Online citations, reference lists, and bibliographies.

Detecting Direct Oral Anticoagulants In Trauma Patients Using Liquid Chromatography-Mass Spectrometry: A Novel Approach To Medication Reconciliation

S. Jayaraman, J. DeAntonio, S. Leichtle, J. Han, Loren K Liebrecht, D. Contaifer, C. Young, C. Chou, Julia Staschen, D. Doan, N. Kumar, L. Wolfe, Tammy Nguyen, Gregory Chenault, R. Anand, J. Bennett, P. Ferrada, S. Goldberg, L. Procter, E. Rodas, A. P. Rossi, James F. Whelan, V. Feeser, Michael J. Vitto, Beth Broering, S. Hobgood, M. Mangino, M. Aboutanos, L. M. Bachmann, D. Wijesinghe
Published 2019 · Biology

Cite This
Download PDF
Analyze on Scholarcy
Background Accurate medication reconciliation in trauma patients is essential but difficult. Currently there is no established clinical method of detecting direct oral anticoagulants (DOACs) in trauma patients. We hypothesized that a liquid chromatography-mass spectrometry (LCMS) based assay can be used to accurately detect DOACs in trauma patients upon hospital arrival. Methods Plasma samples were collected from 356 patients who provided informed consent including-10 healthy controls, 19 known positive or negative controls and 327 trauma patients over 65 years of age who were evaluated at our large, urban Level 1 Trauma Center. The assay methodology was developed in healthy and known controls to detect apixaban, rivaroxaban and dabigatran using LCMS and then applied to 327 samples from trauma patients. Standard medication reconciliation processes in the electronic medical record documenting DOAC usage was compared with LCMS results to determine overall accuracy, sensitivity, specificity and positive and negative predictive values (PPV, NPV) of the assay. Results Of 356 patients, 39 were on DOACs (10.96%): 21 were on Apixaban, 14 on rivaroxaban and 4 on dabigatran. The overall accuracy of the assay for detecting any DOAC was 98.60%, with a sensitivity of 94.87% and specificity of 99.06%, (PPV 92.50% and NPV 99.37%). The assay detected apixaban with a sensitivity of 90.48% and specificity of 99.11% (PPV 86.36% and NPV 99.40%). There were three false positive results and two false negative LCMS results for apixaban. Dabigatran and rivaroxaban were detected with 100% sensitivity and specificity. Conclusions This LCMS-based assay was highly accurate in detecting DOACs in trauma patients. Further studies need to confirm the clinical efficacy of this LCMS assay and its value for medication reconciliation in trauma patients. Study type: diagnostic test Basic Science paper: therefore does not require a level of evidence.
This paper references
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
C. Pollack (2017)
Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions
Matthias Ebner (2017)
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Jaime H. Noguez (2016)
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review
B. Samuelson (2017)
Medications and patient safety in the trauma setting: a systematic review
J. DeAntonio (2019)
Epidemiology and outcomes of missing admission medication history in severe trauma: A retrospective study
Matthew R Miller (2017)
Medication Reconciliation During Transitions of Care as a Patient Safety Strategy
J. Kwan (2013)
Determination of dabigatran, rivaroxaban and apixaban by ultra‐performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
E. M. H. Schmitz (2014)
Emergency surgery and trauma in patients treated with the new oral anticoagulants: Dabigatran, rivaroxaban, and apixaban
Matthew L. Moorman (2014)
崇行 中島 (2012)
Monitoring and reversal of direct oral anticoagulants.
A. Cuker (2015)
Evaluation of medication reconciliation in a trauma unit
O. Pascual (2015)
Improving best possible medication history with vulnerable patients at an urban safety net academic hospital using pharmacy technicians
S. Sadasivaiah (2017)
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
João D. Dias (2015)
Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
M. Schellings (2016)
Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients.
Daniel A Bonville (2011)
National Trends in Ambulatory Oral Anticoagulant Use.
G. Barnes (2015)
Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.
A. Martı́nez-Rubio (2016)
Metabolomics and Precision Medicine in Trauma: The State of the Field
Sudha Jayaraman (2018)
JCAHO'S National Patient Safety Goals 2006.
K. Catalano (2006)
Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?
G. Lippi (2014)
Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: A long-term analysis of risk versus benefit
Tazo S Inui (2014)
Medication reconciliation in a rural trauma population.
S. Miller (2008)
Testing and monitoring direct oral anticoagulants.
J. Connors (2018)
The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI
M. Zeeshan (2018)
Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry
Tracey Gous (2014)
The accuracy of emergency department medication history as determined by mass spectrometry analysis of urine: a pilot study.
Allyson A. Kreshak (2015)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. Connolly (2019)
Predictors of mortality in geriatric trauma patients: A systematic review and meta-analysis
Ammar Hashmi (2014)
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
T. Hu (2016)
Point‐of‐Care Coagulation Tests Monitoring of Direct Oral Anticoagulants and Their Reversal Therapy: State of the Art
G. Iapichino (2017)
Standardization as a mechanism to improve safety in health care.
J. Rozich (2004)
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Tuukka A Helin (2013)
An Insurer's Care Transition Program Emphasizes Medication Reconciliation, Reduces Readmissions And Costs.
J. Polinski (2016)
Incidence and predictors of intracranial hemorrhage after minor head trauma in patients taking anticoagulant and antiplatelet medication.
Edward S. Brewer (2011)
Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis
Sarah Lee (2018)
New anticoagulants: A concise review
L. Baumann Kreuziger (2012)
Rapid point-of-care identification of oral medications in gastric lavage content by ambient mass spectrometry in the emergency room.
Chi-Wei Lee (2016)
Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
C. Becattini (2012)
Metabolomics, a Powerful Tool for Agricultural Research
He Tian (2016)
Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.
S. Vazquez (2018)
A Time and Motion Study of Pharmacists and Pharmacy Technicians Obtaining Admission Medication Histories
Caroline B Nguyen (2017)
A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Jennifer Lagoutte-Renosi (2018)

Semantic Scholar Logo Some data provided by SemanticScholar